Zalutumumab  (Synonyms: 2F8; HUMAX-EGFR)

Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC₅₀s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer^[1][2][3].

Human IgG1(K214R) kappa

Human IgG1 (K214R) kappa, Isotype Control

Human

ERBB1/EGFR/HER1

Zalutumumab (0-1 μM; 60 min) effectively blocks EGF-induced EGFR activation with an IC₅₀ value of 1.3 nM^[2].
Zalutumumab (0-1 μM; 96 h) affects proliferation of A431 cells^[2].
Zalutumumab (10 μg/mL; 24 h) induces a comparable percentage of specificlysis of A431 cells with mouse macrophages^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zalutumumab (5 mg/kg; i.p. 2 h after tumor induction) affects tumor growth in A431 xenograft models^[3].
Zalutumumab (0.5 and 5 mg/kg; i.p. once ) delays tumor growth when mice with tumor volumes of 80-100 mm^3[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1956  [NCBI]

P00533

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.52 kDa

667901-13-5

Liquid

Colorless to light yellow

[Zalutumumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human EGFR Protein (ECD, His Tag) can bind Zalutumumab. The EC₅₀ for this effect is 5.92 ng/mL.
• 
  Flow Cytometry analysis of A431 cells labelling ERBB1/EGFR/HER1 (red) with Zalutumumab (anti-ERBB1/EGFR/HER1) (HY-P99155). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1(K214R) kappa (HY-P99995). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Schick U, et al. Zalutumumab in head and neck cancer. Expert Opin Biol Ther. 2012 Jan;12(1):119-25.  [Content Brief]

  [2]. Lammerts van Bueren JJ, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6109-14.  [Content Brief]

  [3]. Overdijk MB, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 2011 Sep 15;187(6):3383-90.  [Content Brief]